138 related articles for article (PubMed ID: 34137699)
21. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
[TBL] [Abstract][Full Text] [Related]
22. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
23. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
25. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
26. Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - High mortality rate in infected patients with haematologic malignancies.
Biernat MM; Zińczuk A; Biernat P; Bogucka-Fedorczuk A; Kwiatkowski J; Kalicińska E; Marciniak D; Simon K; Wróbel T
J Clin Virol; 2020 Sep; 130():104574. PubMed ID: 32769026
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
Aumann S; Tsubary U; Nachmias B; Ben Yehuda D; Lavie D; Goldschmidt N; Vainstein V; Libster D; Saban R; Shaulov A; Israel S; Avni B; Grisariu S; Bdolah-Amram T; Gatt M; Zimran E
Eur J Haematol; 2023 Jul; 111(1):135-145. PubMed ID: 37096337
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
[TBL] [Abstract][Full Text] [Related]
29. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
[TBL] [Abstract][Full Text] [Related]
30. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
31. SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors.
Dada A; Elhassan K; Bawayan RM; Albishi G; Hefni L; Bassi S; Sobahy T; Cupler E; AlBaz N; Wali G; Alraddadi B; Alshukairi AN
Intervirology; 2022; 65(4):230-235. PubMed ID: 35378533
[TBL] [Abstract][Full Text] [Related]
32. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
Goudsmit A; Cubilier E; Meert AP; Aftimos P; Stathopoulos K; Spilleboudt C; Loizidou A
Support Care Cancer; 2021 Nov; 29(11):6271-6278. PubMed ID: 33851236
[TBL] [Abstract][Full Text] [Related]
34. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
35. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.
Modemann F; Niederwieser C; Weisel K; Bokemeyer C; Fiedler W; Ghandili S
Leuk Lymphoma; 2022 Mar; 63(3):664-671. PubMed ID: 34668809
[TBL] [Abstract][Full Text] [Related]
37. Nosocomial COVID-19. Prospective study in a referral hospital.
Escolà-Vergé L; Borràs-Bermejo B; Los-Arcos I; Esperalba J; Ferrer C; Fernández-Hidalgo N
Med Clin (Barc); 2022 Aug; 159(3):134-136. PubMed ID: 34384612
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis.
Sajmi S; Goutham K; Arumugam V; Gopalakrishnan N; Lamech TM; Aiswarya D; Krishna R; Vathsalyan P; Kannan BS; Solomon D; Nithya G; Sastry BVRH; Sakthirajan R
Hemodial Int; 2021 Oct; 25(4):515-522. PubMed ID: 34133062
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
40. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
